natgillin/translations-raw huggingface dataset:
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Xeloda.
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Xeloda, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Xgeva.
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Yellox.
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z zdravilom in priporočila glede pogojev uporabe zdravila Yellox.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Yervoy.
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Yervoy, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z zdravilom in priporočila glede pogojev njegove uporabe.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Zaltrap.
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Zaltrap, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Zebinix.
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Zebinix, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Zelboraf.
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Zelboraf, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Zinforo.
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Zinforo, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Zyclara.
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Zyclara, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Zytiga.
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Zytiga, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
It explains how the Committee for Medicinal products for Human Use (CHMP) assessed the studies performed, to reach its recommendations on how to use the medicine.
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil opravljene študije, na podlagi katerih je oblikoval priporočila glede uporabe zdravila.
It further induces the internalisation of EGFR, which can lead to down- regulation of EGFR.
Potem sproži obrat EGFR navznoter, kar bi lahko vodilo do efektivnega zmanjšanja števila EGFR.
It has a large volume of distribution (range of means 43 to 114 l/m2).
Ima velik volumen porazdelitve (razpon sredin 43 do 114 l/m2).
It has a primary amino acid sequence that is comparable to the Ala148 allelic form of plasma-derived factor IX, and some post-translational modifications of the recombinant molecule are different from those of the plasma-derived molecule.
Ima primarno aminokislinsko sekvenco, ki je primerljiva z alelno obliko Ala148 iz plazme pridobljenega faktorja IX, in nekatere posttranslacijske modifikacije rekombinantne molekule se razlikujejo od tistih v molekuli, pridobljeni iz plazme.
It has a very low potential to decrease mitochondrial DNA content, is not permanently incorporated into mitochondrial DNA, and does not act as an inhibitor of mitochondrial DNA polymerase gamma.
Ima zelo majhen potencial za zmanjševanje vsebnosti mitohondrijske DNA, v mitohondrijsko DNA se ne vključi permanentno in ne deluje kot zaviralec mitohondrijske DNA-polimeraze gama.
It has also been compared with latanoprost (another prostaglandin analogue used in glaucoma) in a six-month study involving 269 patients.
Zdravilo Lumigan so primerjali tudi z latanoprostom (drugim prostaglandinskim analogom, ki se uporablja za zdravljenje glavkoma) v šestmesečni študiji, ki je
It has also been demonstrated that Synflorix induces an immune response to the cross-reactive serotype 19A with 48.8% (95% CI: 42.9; 54.7) of vaccinees reaching an OPA titre  8 one month after a booster dose.
Dokazano je bilo tudi, da cepivo Synflorix inducira imunski odziv na navzkrižno reaktivni serotip 19A pri 48,8 % (95 % IZ: 42,9, 54,7) cepljenih, ki dosežejo titer OPA  8 en mesec po obnovitvenem odmerku.
It has also been shown to delay multiple myeloma from coming back following treatment.
Izkazalo se je tudi, da zdravilo Revlimid odloži ponovitev diseminiranega plazmocitoma po zdravljenju.
It has also been studied in patients who were already using metformin, a sulphonylurea, or both metformin and a sulphonylurea.
Proučevano je bilo tudi pri bolnikih, ki so že jemali metformin, sulfonilsečnino ali oboje.
it has become stuck to itself or another surface
če se je zlepil skupaj ali pa na drugo površino,
It has been demonstrated that EPP patients receiving SCENESSE had more exposure to direct sunlight (10:00 to 18:00 hours) during a 180 day trial period compared to placebo recipients (p=0.044; SCENESSE arithmetic mean: 115.6 h, median 69.4h; placebo mean 60.6h, median 40.8h).
Izkazalo se je, da so bili bolniki z EPP, ki so prejemali zdravilo SCENESSE, dlje časa izpostavljeni neposredni sončni svetlobi (od 10:00 do 18:00 ure) v 180-dnevnem preskusnem obdobju kot prejemniki placeba (p = 0,044; aritmetično povprečje SCENESSE: 115,6 h, mediana 69,4 h; povprečje placebo 60,6 h, mediana 40,8 h).
It has been demonstrated that once reconstituted Myocet has a chemical and physical in-use stability at room temperature for up to 8 hours or in a refrigerator (2C-8C) for up to 5 days.
Dokazano je, da ima Myocet po rekonstituciji kemično in fizikalno stabilnost med uporabo do 8 ur pri sobni temperaturi in do 5 dni v hladilniku (2 °C–8 °C).
It has been demonstrated that the vaccine, when administered as recommended to piglets from 3 weeks of age induces active immunisation against Porcine Circovirus Type 2 (PCV2) and is able to reduce viral load in blood and lymphoid tissues, and the lesions in lymphoid tissues caused by porcine circovirus infection, as well as to reduce clinical signs –including loss of daily weight gain- and death associated with Post-Weaning Multisystemic Wasting Syndrome (PMWS).
Ugotovljeno je bilo, da cepivo, ki se v skladu s priporočili injicira pujskom, starejšim od 3 tednov, vzpostavi aktivno imunizacijo proti prašičjemu cirkovirusu tipa 2 (PCV2), zmanjša virusno breme v krvi in limfoidnem tkivu, deluje proti lezijam v limfoidnem tkivu, ki jih povzroča okužba s prašičjim cirkovirusom, in ublaži klinične znake, vključno s pomanjkanjem dnevnega pridobivanja telesne mase, ter preprečuje pogin, povezan z multisistemskim sindromom hiranja po odstavitvi (PMWS).
It has been made using a ‘recombinant DNA technique’ (when genes are inserted into an organism) to carry the H5 (haemagglutinin 5) and N3 (neuraminidase 3) antigens.
Proizveden je bil z uporabo »rekombinantne DNK tehnologije« (pri tem se geni vstavijo v organizem) za prenašanje antigenov H5 (hemaglutinin 5) in N3 (nevraminidaza 3).
It has been observed that patients with low platelet counts (<200,000/mm3) at the start of therapy are more likely to develop thrombocytopenia during treatment.
Opažali so, da so bili bolniki, ki so imeli na začetku zdravljenja nizko število trombocitov (<200.000/mm3), bolj nagnjeni k razvoju trombocitopenije med zdravljenjem.
It has been proposed that aripiprazole’s efficacy in schizophrenia and Bipolar I Disorder is mediated through a combination of partial agonism at dopamine D2 and serotonin 5-HT1A receptors and antagonism of serotonin 5-HT2A receptors.
Učinkovitost aripiprazola pri shizofreniji in bipolarni motnji I je domnevno posledica kombinacije delnega agonizma na dopaminskih receptorjih D2 in serotoninskih receptorjih 5-HT1A ter antagonizma na serotoninskih receptorjih 5-HT2A.
It has been proposed that aripiprazole’s efficacy in schizophrenia and Bipolar I Disorder is mediated through a combination of partial agonism at dopamine D2 and serotonin 5HT1a receptors and antagonism of serotonin 5HT2a receptors.
Učinkovitost aripiprazola pri shizofreniji in bipolarni motnji I je domnevno posledica kombinacije delnega agonizma na dopaminskih receptorjih D2 in serotoninskih receptorjih 5-HT1a ter antagonizma na serotoninskih receptorjih 5-HT2a.
It has been proposed that aripiprazole’s efficacy in schizophrenia and Bipolar I Disorder is mediated through a combination of partial agonism at dopamine D2 and serotonin HT1A receptors and antagonism of serotonin 5-HT2A receptors.
Učinkovitost aripiprazola pri shizofreniji in bipolarni motnji I je domnevno posledica kombinacije delnega agonizma na dopaminskih receptorjih D2 in serotoninskih receptorjih 5-HT1A ter antagonizma na serotoninskih receptorjih 5-HT2A.
It has been proposed that aripiprazole’s efficacy in schizophrenia is mediated through a combination of partial agonism at dopamine D2 and serotonin 5-HT1A receptors and antagonism at serotonin 5-HT2A receptors.
Učinkovitost aripiprazola pri shizofreniji je domnevno posledica kombinacije delnega agonizma na dopaminskih receptorjih D2 in serotoninskih receptorjih 5-HT1A ter antagonizma na serotoninskih receptorjih 5-HT2A.
It has been shown in dogs that plasma deslorelin levels peak 7 to 35 days following administration of an implant containing 5 mg radiolabelled deslorelin.
Koncentracija deslorelina v plazmi je pri psih najvišja 7 do 35 dni po vsaditvi implantata, ki vsebuje 5 mg radioaktivno označenega deslorelina.
It has been shown in experimental models to increase the levels of a ‘neurotransmitter’ called gamma aminobutyric acid (GABA) in the brain.
Študije na poskusnih modelih so pokazale, da utegne zvišati raven živčnega prenašalca, imenovanega gama-aminomaslena kislina (GABA), v možganih.
It has been shown that in the offspring of women with epilepsy, the prevalence of malformations is two to three times greater than the rate of approximately 3 % in the general population.
Raziskave so pokazale, da je pri potomcih žensk z epilepsijo razširjenost malformacij dve- do trikrat večja kot pri splošni populaciji, kjer je 3-odstotna.
It has been shown that in the offspring of women with epilepsy, the prevalence of malformations is two to three times greater than the rate of approximately 3% in the general population.
Dokazano je, da je pogostnost malformacij pri otrocih žensk z epilepsijo dva do trikrat večja od pogostnosti približno 3 % v splošni populaciji.
It has been shown that in the offspring of women with epilepsy, the prevalence of malformations is two to three times greater than the rate of approximately 3% in the general population.
Raziskave so pokazale, da je pri potomcih žensk z epilepsijo razširjenost malformacij dve- do trikrat večja kot pri splošni populaciji, kjer je 3-odstotna.
It has been shown that saquinavir is approximately 97 % bound to plasma proteins up to 30 g/ml.
Prikazano je bilo, da se sakvinavir približno 97 % veže na plazemske beljakovine do 30 µg/ml.
It has been shown that taking all doses at the appropriate times:
Pokazalo se je, da se ob jemanju vseh odmerkov ob ustreznem času:
It has been shown to prolong survival of allogeneic transplants in animals and significantly improved graft survival in all types of solid organ transplantation in man.
Pokazalo se je, da podaljša preživetje alogenskih presadkov pri živalih in značilno izboljša preživetje presadka pri vseh vrstah presaditev čvrstih organov pri ljudeh.
It has been suggested that conditioning regimens containing fludarabine were associated with higher incidence of opportunistic infections after transplantation because of the immunosuppressive effect of fludarabine.
Domnevno naj bi bile pripravljalne sheme s fludarabinom po transplantacijah povezane z višjo incidenco oportunističnih okužb, ker fludarabin deluje imunosupresivno.
It has been used in medicines for several decades.
V zdravilih se uporablja že nekaj desetletij.
It has immunomodulating/ immunosuppressive characteristics, acts as an antiproliferative agent, and displays anti-inflammatory properties.
Učinkuje imunomodulacijsko/imunosupre- sivno, deluje antiproliferacijsko in protivnetno.
It has no anti-bacterial effects.
Nima nobenih antibakterijskih učinkov.
It has not been determined if phenylacetate is secreted in human milk and therefore the use of PHEBURANE is contra-indicated during breast-feeding (see section 4.3).
Ni znano, ali fenilacetat prehaja v materino mleko, zato je uporaba zdravila PHEBURANE med dojenjem kontraindicirana (glejte poglavje 4.3).
It has not been determined whether cuSCC is related to Odomzo treatment.
Povezave razvoja ploščatoceličnega karcinoma kože z zdravljenjem z zdravilom Odomzo niso dokazali.
It has not been studied in combination with ribavirin in these children.
Pri teh otrocih zdravilo v kombinaciji z ribavirinom ni bilo proučevano.
it has not passed its expiry date
da rok uporabnosti ni pretečen,
it has other material stuck to it it is the second time it has become loose or has fallen off.
če se je nanj prilepila druga snov ali če je že drugič popustil ali odpadel.
It has similar immunostimulatory effects as natural MDP with the additional advantage of a longer half-life in plasma.
Ima podobne imunostimulativne učinke kot naravni MDP, njegova dodatna prednost pa je daljša razpolovna doba v plazmi.
It has the same dosage and frequency of administration as olanzapine film- coated tablets.
Odmerek in pogostnost dajanja sta enaka kot pri filmsko obloženih tabletah olanzapin.
It has the same dosage and frequency of administration as olanzapine tablets.
Odmerjanje je enako, prav tako pogostost jemanja.
It has to be ensured that the analysis is carried out by a qualified laboratory.
Zagotoviti morate, da bo analizo opravil usposobljen laboratorij.
It has to be ensured that the analysis is carried out by a qualified laboratory.
Zagotoviti morate, da bodo opravili analizo v usposobljenem laboratoriju.
It has to be noted that the switch from the oral solution to the capsule formulation of Aptivus could be associated with decreased exposure.
Vedeti je treba, da se lahko po prehodu z zdravila Aptivusperoralna raztopina na zdravilo Aptivus kapsule zmanjša izpostavljenost zdravilu.
It helps to control your body’s immune system after you have received a kidney transplant.
Po presaditvi ledvice pomaga nadzorovati vaš imunski sistem.
It helps to destroy the patient’s existing blood-making cells, resulting in the successful transplantation of new cells, improved survival and a reduced risk of the diseases coming back.
Pomaga uničiti bolnikove obstoječe krvotvorne celice, kar se kaže v uspešni presaditvi novih celic, daljšem preživetju in zmanjšanem tveganju ponovitve bolezni.
It helps to prevent other bone problems that may need surgery or radiotherapy
Pomaga preprečiti druge težave s kostmi, zaradi česar bi potrebovali operacijo ali radioterapijo.
It helps to prevent other bone problems that may need surgery or radiotherapy.
Pomaga preprečiti druge težave s kostmi, zaradi česar bi potrebovali operacijo ali radioterapijo.
It helps to prevent your bones from breaking (fractures)
Pomaga preprečiti zlome (frakture) kosti.
It helps to prevent your bones from breaking (fractures).
Pomaga preprečevati zlome kosti.
It helps to prevent your bones from breaking (fractures).
Pomaga preprečiti zlome (frakture) kosti.
It includes a total of 2,431 patients on Gilenya (0.5 or 1.25 mg).
Skupno obsega 2.431 bolnikov, ki so prejemali zdravilo Gilenya (0,5 ali 1,25 mg).
It increases the effects of levodopa and helps to relieve the symptoms of Parkinson’s disease and movement problems.
Poveča učinke levodope in pomaga ublažiti simptome Parkinsonove bolezni in težave z gibanjem.
It induces an active and specific immunity against Bluetongue Virus in the vaccinated animal.
Pri cepljeni živali povzroči nastanek aktivne in specifične imunosti proti virusu bolezni modrikastega jezika.
It induces an active and specific immunity against bluetongue virus in the vaccinated animal.
Pri cepljeni živali sproži nastanek aktivne in specifične imunosti proti virusu bolezni modrikastega jezika.
It induces an active and specific immunity against Bluetongue virus serotype 8 in the vaccinated animal.
Pri cepljeni živali povzroči nastanek aktivne in specifične imunosti proti virusu modrega jezika, serotip 8.
It induces an active and specific immunity against bluetongue virus serotype 8 in the vaccinated animal.
Pri cepljeni živali sproži nastanek aktivne in specifične imunosti proti virusu modrega jezika, serotip 8.
It induces an active and specific immunity against bluetongue virus serotypes 2 and 4 in the vaccinated animals.
Pri cepljenih živalih sproži nastanek aktivne in specifične imunosti proti virusu modrikastega jezika, serotip 2 in 4.
It induces an active and specific immunity against Muscovy duck parvovirosis and Derzsy’s disease in the vaccinated birds.
Cepivo povzroči nastanek aktivne in specifične imunosti proti parvovirozi rac moškatnih bleščavk in Derzsiyevi bolezni pri cepljenih pticah.
It inhibits both Ambler class A and class C β-lactamases and some class D enzymes, including extended-spectrum β-lactamases (ESBLs), KPC and OXA-48 carbapenemases, and AmpC enzymes.
Zavre betalaktamaze razreda A in razreda C po Amblerju ter nekatere encime razreda D, vključno z betalaktamazami razširjenega spektra (ESBL – extended-spectrum beta- lactamases), karbapenemazami KPC in OXA-48 ter encimi AmpC.
It is a breath test for adolescents from the age of 12 and adults to determine the presence of bacterium Helicobacter pylori in the stomach.
Je dihalni test za mladostnike nad 12 let in za odrasle za ugotavljanje prisotnosti bakterije Helicobacter pylori v želodcu.
It is a breath test for children aged 3-11 years to determine the presence of bacterium Helicobacter pylori in the stomach or duodenum.
Je dihalni test za otroke od 3 do 11 let za ugotavljanje prisotnosti bakterije Helicobacter pylori v želodcu ali dvanajsterniku.
It is a CHMP concern that the data from the THIN (The Health Improvement Database) study suggests that approx 70% of the users are outside indication.
Odbor za zdravila za uporabo v humani medicini skrbi, da morda podatki iz študije THIN (The Health Improvement Database – Banka podatkov o izboljšanju zdravja) kažejo, da približno 70% bolnikov zdravilo uporablja zunaj odobrenih indikacij.
It is a clear to slightly pearly (opalescent), colourless to pale yellow liquid.
Je bistra do rahlo lesketajoča se (opalescentna), brezbarvna do bledo rumena raztopina.
It is a complex (a type of chemical) made up of a radioactive element, samarium-153 (153Sm), bound to another chemical called ‘ethylene diamine tetra methylene phosphonic acid’ (EDTMP).
Gre za spojino (vrsta kemične snovi), sestavljeno iz radioaktivnega elementa samarija-153 (153Sm), ki je vezan na drugo kemično snov, imenovano etilen diamin tetrametilen fosfonska kislina (EDTMP).
It is a copy of a protein called ‘bone morphogenetic protein 2’ (BMP-2), which is produced naturally by the body and helps with the formation of new bone tissue.
Učinkovina je kopija beljakovine, imenovane „protein za morfogenezo kosti 2“ (BMP-2), ki se naravno tvori v telesu in pomaga pri tvorjenju novega kostnega tkiva.
It is a cytotoxic (a medicine that kills cells that are dividing, such as cancer cells), which belongs to the ‘anti-metabolite’ group.
Je citotoksin (zdravilo, ki ubija deleče se celice, kot so rakaste celice), ki spada v skupino antimetabolitov.
It is a disposable pen containing 3 mL (300 units) of U- 100 insulin.
Je peresnik za enkratno uporabo, ki vsebuje 3 ml (300 enot) i.e.-100 insulina.
It is a gamma-amino butyric acid (GABA) agonist, which means that it attaches to the receptors for the neurotransmitter GABA and activates them.
Je agonist receptorjev gama-aminomaslene kisline (GABA), kar pomeni, da se veže na receptorje za živčne prenašalce GABA in jih aktivira.
It is a humanized monoclonal antibody that binds specifically to the α4β7 integrin, which is preferentially expressed on gut homing T helper lymphocytes.
Je humanizirano monoklonsko protitelo, ki se specifično veže na integrin α4β7, ki je izražen predvsem na celicah T pomagalkah v črevesu.
It is a medicine used in adults to treat constipation specifically caused by pain medicines, called opioids, (e.g. morphine, oxycodone, fentanyl, tramadol, codeine) taken on a regular basis.
Uporabljamo ga za zdravljenje zaprtosti, ki je izrecno posledica rednega jemanja protibolečinskih zdravil, imenovanih opioidi (npr. morfin, oksikodon, fentanil, tramadol, kodein).
It is a parasiticide which is active against many internal and external parasites.
Je paraziticid, ki deluje na mnoge notranje in zunaje zajedavce.
It is a potent and selective inhibitor of the cyclooxygenase 2 enzyme (COX-2).
Je učinkovit in selektiven zaviralec encima ciklooksigenaza 2 (COX-2).
It is a powder and solvent that are mixed together to make a solution for injection.
Sestavljata ga prašek in vehikel, ki se zmešata za pripravo raztopine za injiciranje.
It is a suspension for injection that contains parts (‘surface antigens’) of the influenza (flu) virus.
Je suspenzija za injiciranje, ki vsebuje dele (površinske antigene) virusa influence (gripe).
It is a synthetic prostamide, structurally related to prostaglandin F2 (PGF2) that does not act through any known prostaglandin receptors.
Je sintetični prostamid, strukturalno podoben prostaglandinu F2α (PGF2α), ki ne deluje preko kateregakoli znanega prostaglandinskega receptorja.
It is a tridentate ligand that binds iron with high affinity in a 2:1 ratio.
trovalenten ligand, ki veže železo z visoko afiniteto v razmerju 2:1.
It is a ‘generic medicine’.
Je „generično zdravilo“.
It is a ‘generic medicine’.
Zdravilo Tadalafil Mylan je „generično zdravilo“.
It is a ‘hybrid medicine’.
Je „hibridno zdravilo“.